Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P1151 | DOI: 10.1530/endoabs.56.P1151

17 views


1Haydarpaşa Education Hospital, Endocrinology and Metabolism Section, İstanbul, Turkey; 2Namık Kemal University, Arts and Sciences Faculty, Department of Molecular Biology and Genetics, Tekirdağ, Turkey; 3Kartal Dr. Lütfi Kırdar Education and Training Hospital, Pathology Department, İstanbul, Turkey; 4Kartal Dr. Lütfi Kırdar Education and Training Hospital, Department of Medical Oncology, İstanbul, Turkey; 5Marmara University, School of Medicine, Department of Endocrinology and Metabolism, İstanbul, Turkey.


Introduction: BRAF V600E substitution is one of the most common mutation in PTC in different populations, and is associated with poor prognosis of the classical variant of PTC (CVPTC) such as extrathyroidal expansion, vascular invasion, lymph node metastasis and recurrence of the disease. The purpose of this study is to determine the prevalence of BRAF V600E mutation in subcell- types of the PTCs in Turkish population.

Materials and methods: A total of 191 patients diagnosed with PTC admitted to Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, were retrospectively analyzed. Clinical and pathologic factors including age, gender, PTC subtype, thyroid capsule invasion, extrathyroidal tissue invasion, and lymph node metastasis were obtained from patients’ medical records. DNA was extracted from FFPE tissue samples. The BRAF gene region including V600E mutation was screened by using high resolution melting curve analysis (HRMA) and the precise localisation of mutations were confirmed by using DNA sequencing with Sanger method.

Results: One hundred and nine patients were diagnosed as CVPTC, 37 were macrocarcinoma and 72 were microcarcinoma. Sixty-five were diagnosed as Follicular variant of PTC (FVPTC), seventeen were diagnosed as Oncocytic variant of PTC (OVPTC). A mutation at 15th exon of the BRAF gene was detected in 23 of the 37 macroCVPTC patients. Nineteen out of twenty- three of these mutations were BRAF V600E, 1/23 was BRAF V600V and 3/23 were BRAF F583Y. Seventeen of the 72 microCVPTC cases were harbored with one of the BRAF mutations. Fifteen of them were BRAF V600E (20.8%) and only two of them were V600V mutation. Two mutations were detected in 37 macroFVPTC patients, one being BRAF V600V, while the other was BRAF V600E mutation (2.7%). Besides, two of the 28 microFVPTC cases (7.1%) were harbored with BRAFV600E mutation. Four of 12 macroOVPTC cases had one of the BRAF mutation. One of them was BRAFF595L and the others were BRAFV600E (25%). One of the microOVPTC case had BRAFV600V mutation. When mutation positive tumor samples were compared with mutation negative ones in classical variant group(CVPTC), thyroid capsule invasion, extrathyroidal tissue invasion, and lymph node metastasis were associated with BRAF mutations independent from tumor size (P<0.05 for each).

Conclusion: Considering that BRAF V600E mutation is correlated with poor prognosis of the disease according to the obtained data, larger population based studies are necessary in order to follow up the prognosis of the PTC patients in Turkish population.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.